If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Understanding the testing and evaluation process is crucial for early detection and management. The medical community has long emphasized the importance of balancing therapeutic benefits with potential risks, and this page provides a clear overview of PML monitoring and diagnosis.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients without other immunosuppression have developed the disease. Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, prescribers must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri. They must determine every six months whether patients should continue treatment and, if so, authorize treatment for another six months. Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
FDA adverse-event reports most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, drug ineffective, urinary tract infection, pain, balance disorder, hypoesthesia, pain in extremity, muscular weakness, nasopharyngitis, nausea, dizziness, mobility decreased, stress, cognitive disorder, muscle spasms, depression, and arthralgia (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, the boxed warning and risk factors underscore the seriousness of PML as a known adverse effect. For patients in Texas who have developed PML after Tysabri exposure, legal considerations involve the statute of limitations, which is the time limit for filing a lawsuit. In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because PML symptoms may develop gradually and be mistaken for multiple sclerosis relapse or other conditions. The latency between Tysabri exposure and PML diagnosis can be months to years, and the statute of limitations clock typically starts when the patient or their representative knows or should know that the injury was caused by Tysabri. Adequacy of warnings is a central issue in such cases. The Tysabri label includes a boxed warning and detailed risk factor information, but questions may arise about whether prescribers and patients were adequately informed of the risk, especially in the context of the TOUCH program's monitoring requirements. If a patient was not properly monitored or if warning signs were missed, the manufacturer's liability may be contested.
Attorney considerations for affected patients include gathering medical records documenting Tysabri use, PML diagnosis, and the timeline of symptoms; consulting with medical experts to establish causation; and filing a claim within the applicable statute of limitations. The mechanistic pathway linking Tysabri to PML involves the drug's mechanism of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing JC virus to reactivate and cause PML. The risk is highest in patients with anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use, as noted in the prescribing information. In summary, Tysabri carries a known risk of PML, with specific risk factors and monitoring requirements. For Texas patients who develop PML, the statute of limitations for legal action is generally two years from discovery of the injury. Adequacy of warnings and adherence to monitoring protocols are key factors in potential litigation. Patients and their families should seek legal counsel promptly to preserve their rights.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Tysabri, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This means that if you or a loved one developed PML after Tysabri exposure, you typically have two years from the date of diagnosis or when you reasonably should have known the injury was caused by Tysabri to file a lawsuit.
According to the prescribing information, three factors increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered when initiating and continuing treatment.
Under the TOUCH Prescribing Program, prescribers must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri. They must determine every six months whether patients should continue treatment and authorize treatment for another six months. Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.